Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study

Table 1 Sociodemographics, substance use characteristics and blood parameters of anti-hepatitis C virus positive patients in an Opioid Treatment Program

	Anti-HCV positive, n = 336, n (%)
Female, n (%)	57 (17.0)
Age (yr), median (IQR)	46 (41-50)
Time in OTP (yr), median (IQR)	15.3 (5.6-19.2)
Opiate agonists
Methadone	331 (98.5)
Buprenorphine	5 (1.5)
Antecedent of injection drug use (n = 326)	282 (86.5)
History of incarceration (n = 291)	158 (54.3)
Current substance use (last month) (n = 213), n (%)
Alcohol	101 (47.2)
Cannabis	88 (41.3)
Cocaine	68 (31.9)
Heroin	49 (23.0)
Blood parameters
Leucocyte (× 109/L) (n = 298)	6.7 (5.3-8.6)
Lymphocyte (× 109/L) (n = 296)	2.2 (1.5-2.8)
Platelets (× 109/L) (n = 295)	181 (138-232)
Hemoglobin (mg/dL) (n = 296)	14.3 (13-15.1)
AST (U/L) (n = 284)	31 (21-52)
ALT (U/L) (n = 252)	30 (18-52.5)
GGT (U/L) (n = 242)	44.5 (25-89)
Total bilirubin (mg/dL) (n = 238)	0.5 (0.4-0.7)
Total cholesterol (mg/dL) (n = 210)	168.5 (144-194)
HIV infection, n (%) (n = 334)	160 (47.9)

HCV: Hepatitis C virus; IQR: Interquartile range; OTP: Opioid Treatment Program; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma glutamyl transferase; HIV: Human immunodeficiency virus.

Table 2 Cox regression models for predictors of hepatitis C virus-treatment with direct antiviral agents

	Unadjusted HR (95%CI)	Adjusted HR (95%CI)
Female	0.79 (0.46-1.34)
Age: 5 years increase	1.17 (1.06-1.30)	0.98 (0.81-1.18)
OTP and substance use related variables
Time in OTP (yr)	1.03 (1.01-1.06)	1.02 (0.99-1.05)
Alcohol use (last month)	0.58 (0.37-0.92)	0.72 (0.45-1.17)
Substance use1 (last month)	0.47 (0.30-0.74)	0.48 (0.29-0.80)
Antecedent of injection drug use	1.35 (0.72-2.51)
History of incarceration	1.10 (0.75-1.63)
Co-morbidity
HIV infection	2.23 (1.52-3.28)	1.94 (1.21-3.12)

¹Cannabis, cocaine, heroin. OTP: Opioid Treatment Program; HIV: Human immunodeficiency virus.